1h Free Analyst Time
Speak directly to the analyst to clarify any post sales queries you may have.
1 of 3
FEATURED COMPANIES
- AbbVie Inc.
- Allergan Plc
- Amgen Inc.
- Celgene Corp.
- GlaxoSmithKline Plc
- Pfizer Inc.
- MORE
Global Amyloidosis Therapeutics Market: About this market
The amyloidosis therapeutics market analysis considers sales from systemic amyloidosis and other amyloidosis types. Our analysis also considers the sales of amyloidosis therapeutics in Asia, Europe, North America, and ROW. In 2018, the systemic amyloidosis segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the high prevalence of the condition and recent drug approvals will play a significant role in the systemic amyloidosis segment to maintain its market position. Also, our global amyloidosis therapeutics market report looks at factors such as high prevalence of associated risk factors of amyloidosis, growth of geriatric population, and increasing research funding for rare diseases. However, lack of curative therapies, difficulty in diagnosis, and high cost of approved therapies may hamper the growth of the amyloidosis therapeutics industry over the forecast period.
Global Amyloidosis Therapeutics Market: Overview
Increasing research funding for rare disease
The global amyloidosis therapeutics market has only three approved drugs for the treatment of the condition. Although the amyloidosis is rare, the increasing prevalence of the condition and the lack of approved therapies have resulted in an unmet need for treatment using drugs that are available in the market. This has resulted in the intense R&D of novel therapies by vendors and research institutes for the development of treatment options for amyloidosis. Many organizations, such as Vasculitis Foundation and National Organization for Rare Disorders, have been providing research funding to small or mid-sized companies to complete their clinical trials and launch drugs. This Increasing research funding will lead to the expansion of the global amyloidosis therapeutics market at a CAGR of almost 8% during the forecast period.
Special drug designations
Drugs that treat amyloidosis and therapeutic candidates (under development) for the treatment of the condition have been awarded special drug designations by regulatory bodies considering their proven efficacy. Many such drugs received designations such as the breakthrough drug designation and the orphan drug designation from regulatory bodies such as the US FDA and the EMA. The sponsors of these drugs receive various incentives and tax benefits, encouraging vendors to expedite R&D on new molecules. This development is expected to have a positive impact on the overall market growth.
Competitive Landscape
With the presence of several major players, the global amyloidosis therapeutics market is fragmented. The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading amyloidosis therapeutics manufacturers, that include AbbVie Inc., Allergan Plc, Alnylam Pharmaceuticals Inc., Amgen Inc., Celgene Corp., GlaxoSmithKline Plc, Ionis Pharmaceuticals Inc., Johnson & Johnson Services Inc., Pfizer Inc., and Takeda Pharmaceutical Co. Ltd.
Also, the amyloidosis therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
The amyloidosis therapeutics market analysis considers sales from systemic amyloidosis and other amyloidosis types. Our analysis also considers the sales of amyloidosis therapeutics in Asia, Europe, North America, and ROW. In 2018, the systemic amyloidosis segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the high prevalence of the condition and recent drug approvals will play a significant role in the systemic amyloidosis segment to maintain its market position. Also, our global amyloidosis therapeutics market report looks at factors such as high prevalence of associated risk factors of amyloidosis, growth of geriatric population, and increasing research funding for rare diseases. However, lack of curative therapies, difficulty in diagnosis, and high cost of approved therapies may hamper the growth of the amyloidosis therapeutics industry over the forecast period.
Global Amyloidosis Therapeutics Market: Overview
Increasing research funding for rare disease
The global amyloidosis therapeutics market has only three approved drugs for the treatment of the condition. Although the amyloidosis is rare, the increasing prevalence of the condition and the lack of approved therapies have resulted in an unmet need for treatment using drugs that are available in the market. This has resulted in the intense R&D of novel therapies by vendors and research institutes for the development of treatment options for amyloidosis. Many organizations, such as Vasculitis Foundation and National Organization for Rare Disorders, have been providing research funding to small or mid-sized companies to complete their clinical trials and launch drugs. This Increasing research funding will lead to the expansion of the global amyloidosis therapeutics market at a CAGR of almost 8% during the forecast period.
Special drug designations
Drugs that treat amyloidosis and therapeutic candidates (under development) for the treatment of the condition have been awarded special drug designations by regulatory bodies considering their proven efficacy. Many such drugs received designations such as the breakthrough drug designation and the orphan drug designation from regulatory bodies such as the US FDA and the EMA. The sponsors of these drugs receive various incentives and tax benefits, encouraging vendors to expedite R&D on new molecules. This development is expected to have a positive impact on the overall market growth.
Competitive Landscape
With the presence of several major players, the global amyloidosis therapeutics market is fragmented. The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading amyloidosis therapeutics manufacturers, that include AbbVie Inc., Allergan Plc, Alnylam Pharmaceuticals Inc., Amgen Inc., Celgene Corp., GlaxoSmithKline Plc, Ionis Pharmaceuticals Inc., Johnson & Johnson Services Inc., Pfizer Inc., and Takeda Pharmaceutical Co. Ltd.
Also, the amyloidosis therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
Note: Product cover images may vary from those shown
2 of 3
FEATURED COMPANIES
- AbbVie Inc.
- Allergan Plc
- Amgen Inc.
- Celgene Corp.
- GlaxoSmithKline Plc
- Pfizer Inc.
- MORE
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 08: GEOGRAPHIC LANDSCAPE
PART 10: DRIVERS AND CHALLENGES
Exhibit 01: Product overview
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Type - Market share 2018-2023 (%)
Exhibit 19: Comparison by type
Exhibit 20: Systemic amyloidosis - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Systemic amyloidosis - Year-over-year growth 2019-2023 (%)
Exhibit 22: Other amyloidosis - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Other amyloidosis - Year-over-year growth 2019-2023 (%)
Exhibit 24: Market opportunity by type
Exhibit 25: Customer landscape
Exhibit 26: Market share by geography 2018-2023 (%)
Exhibit 27: Geographic comparison
Exhibit 28: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 29: North America - Year-over-year growth 2019-2023 (%)
Exhibit 30: Top 3 countries in North America
Exhibit 31: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 32: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 33: Top 3 countries in Europe
Exhibit 34: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 35: Proportion of geriatric population in Asia 2009 and 2018
Exhibit 36: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 37: Top 3 countries in Asia
Exhibit 38: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 39: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 40: Top 3 countries in ROW
Exhibit 41: Key leading countries
Exhibit 42: Market opportunity
Exhibit 43: Prevalence/incidence of associated risk factors of amyloidosis
Exhibit 44: Growth of geriatric population 2014-2018 (%)
Exhibit 45: Cost of approved drugs for treatment of amyloidosis in the US
Exhibit 46: Impact of drivers and challenges
Exhibit 47: Drug designations
Exhibit 48: Vendor landscape
Exhibit 49: Landscape disruption
Exhibit 50: Vendors covered
Exhibit 51: Vendor classification
Exhibit 52: Market positioning of vendors
Exhibit 53: AbbVie Inc. - Vendor overview
Exhibit 54: AbbVie Inc. - Business segments
Exhibit 55: AbbVie Inc. - Organizational developments
Exhibit 56: AbbVie Inc. - Geographic focus
Exhibit 57: AbbVie Inc. - Key offerings
Exhibit 58: AbbVie Inc. - Key customers
Exhibit 59: Allergan Plc - Vendor overview
Exhibit 60: Allergan Plc - Business segments
Exhibit 61: Allergan Plc - Organizational developments
Exhibit 62: Allergan Plc - Geographic focus
Exhibit 63: Allergan Plc - Segment focus
Exhibit 64: Allergan Plc - Key offerings
Exhibit 65: Allergan Plc - Key customers
Exhibit 66: Alnylam Pharmaceuticals Inc. - Vendor overview
Exhibit 67: Alnylam Pharmaceuticals Inc. - Business segments
Exhibit 68: Alnylam Pharmaceuticals Inc. - Organizational developments
Exhibit 69: Alnylam Pharmaceuticals Inc. - Key offerings
Exhibit 70: Alnylam Pharmaceuticals Inc. - Key customers
Exhibit 71: Amgen Inc. - Vendor overview
Exhibit 72: Amgen Inc. - Business segments
Exhibit 73: Amgen Inc. - Organizational developments
Exhibit 74: Amgen Inc. - Geographic focus
Exhibit 75: Amgen Inc. - Key offerings
Exhibit 76: Amgen Inc. - Key customers
Exhibit 77: Celgene Corp. - Vendor overview
Exhibit 78: Celgene Corp. - Business segments
Exhibit 79: Celgene Corp. - Organizational developments
Exhibit 80: Celgene Corp. - Geographic focus
Exhibit 81: Celgene Corp. - Key offerings
Exhibit 82: Celgene Corp. - Key customers
Exhibit 83: GlaxoSmithKline Plc - Vendor overview
Exhibit 84: GlaxoSmithKline Plc - Business segments
Exhibit 85: GlaxoSmithKline Plc - Organizational developments
Exhibit 86: GlaxoSmithKline Plc - Geographic focus
Exhibit 87: GlaxoSmithKline Plc - Segment focus
Exhibit 88: GlaxoSmithKline Plc - Key offerings
Exhibit 89: GlaxoSmithKline Plc - Key customers
Exhibit 90: Ionis Pharmaceuticals Inc. - Vendor overview
Exhibit 91: Ionis Pharmaceuticals Inc. - Business segments
Exhibit 92: Ionis Pharmaceuticals Inc. - Organizational developments
Exhibit 93: Ionis Pharmaceuticals Inc. - Key offerings
Exhibit 94: Ionis Pharmaceuticals Inc. - Key customers
Exhibit 95: Johnson & Johnson Services Inc. - Vendor overview
Exhibit 96: Johnson & Johnson Services Inc. - Business segments
Exhibit 97: Johnson & Johnson Services Inc. - Organizational developments
Exhibit 98: Johnson & Johnson Services Inc. - Geographic focus
Exhibit 99: Johnson & Johnson Services Inc. - Segment focus
Exhibit 100: Johnson & Johnson Services Inc. - Key offerings
Exhibit 101: Johnson & Johnson Services Inc. - Key customers
Exhibit 102: Pfizer Inc. - Vendor overview
Exhibit 103: Pfizer Inc. - Business segments
Exhibit 104: Pfizer Inc. - Organizational developments
Exhibit 105: Pfizer Inc. - Geographic focus
Exhibit 106: Pfizer Inc. - Segment focus
Exhibit 107: Pfizer Inc. - Key offerings
Exhibit 108: Pfizer Inc. - Key customers
Exhibit 109: Takeda Pharmaceutical Co. Ltd. - Vendor overview
Exhibit 110: Takeda Pharmaceutical Co. Ltd. - Business segments
Exhibit 111: Takeda Pharmaceutical Co. Ltd. - Organizational developments
Exhibit 112: Takeda Pharmaceutical Co. Ltd. - Geographic focus
Exhibit 113: Takeda Pharmaceutical Co. Ltd. - Key offerings
Exhibit 114: Takeda Pharmaceutical Co. Ltd. - Key customers
Exhibit 115: Validation techniques employed for market sizing
Exhibit 116: Definition of market positioning of vendors
PART 02: SCOPE OF THE REPORT
- Preface
- Currency conversion rates for US$
- Market ecosystem
- Market characteristics
- Market segmentation analysis
- Market definition
- Market sizing 2018
- Market size and forecast 2018-2023
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
- Market segmentation by type
- Comparison by type
- Systemic amyloidosis - Market size and forecast 2018-2023
- Other amyloidosis - Market size and forecast 2018-2023
- Market opportunity by type
PART 08: GEOGRAPHIC LANDSCAPE
- Geographic segmentation
- Geographic comparison
- North America - Market size and forecast 2018-2023
- Europe - Market size and forecast 2018-2023
- Asia - Market size and forecast 2018-2023
- ROW - Market size and forecast 2018-2023
- Key leading countries
- Market opportunity
PART 10: DRIVERS AND CHALLENGES
- Market drivers
- Market challenges
- Increasing awareness about rare diseases
- Special drug designations
- Strategic alliances
- Overview
- Landscape disruption
- Vendors covered
- Vendor classification
- Market positioning of vendors
- AbbVie Inc.
- Allergan Plc
- Alnylam Pharmaceuticals Inc.
- Amgen Inc.
- Celgene Corp.
- GlaxoSmithKline Plc
- Ionis Pharmaceuticals Inc.
- Johnson & Johnson Services Inc.
- Pfizer Inc.
- Takeda Pharmaceutical Co. Ltd.
- Research methodology
- List of abbreviations
- Definition of market positioning of vendors
Exhibit 01: Product overview
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Type - Market share 2018-2023 (%)
Exhibit 19: Comparison by type
Exhibit 20: Systemic amyloidosis - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Systemic amyloidosis - Year-over-year growth 2019-2023 (%)
Exhibit 22: Other amyloidosis - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Other amyloidosis - Year-over-year growth 2019-2023 (%)
Exhibit 24: Market opportunity by type
Exhibit 25: Customer landscape
Exhibit 26: Market share by geography 2018-2023 (%)
Exhibit 27: Geographic comparison
Exhibit 28: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 29: North America - Year-over-year growth 2019-2023 (%)
Exhibit 30: Top 3 countries in North America
Exhibit 31: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 32: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 33: Top 3 countries in Europe
Exhibit 34: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 35: Proportion of geriatric population in Asia 2009 and 2018
Exhibit 36: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 37: Top 3 countries in Asia
Exhibit 38: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 39: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 40: Top 3 countries in ROW
Exhibit 41: Key leading countries
Exhibit 42: Market opportunity
Exhibit 43: Prevalence/incidence of associated risk factors of amyloidosis
Exhibit 44: Growth of geriatric population 2014-2018 (%)
Exhibit 45: Cost of approved drugs for treatment of amyloidosis in the US
Exhibit 46: Impact of drivers and challenges
Exhibit 47: Drug designations
Exhibit 48: Vendor landscape
Exhibit 49: Landscape disruption
Exhibit 50: Vendors covered
Exhibit 51: Vendor classification
Exhibit 52: Market positioning of vendors
Exhibit 53: AbbVie Inc. - Vendor overview
Exhibit 54: AbbVie Inc. - Business segments
Exhibit 55: AbbVie Inc. - Organizational developments
Exhibit 56: AbbVie Inc. - Geographic focus
Exhibit 57: AbbVie Inc. - Key offerings
Exhibit 58: AbbVie Inc. - Key customers
Exhibit 59: Allergan Plc - Vendor overview
Exhibit 60: Allergan Plc - Business segments
Exhibit 61: Allergan Plc - Organizational developments
Exhibit 62: Allergan Plc - Geographic focus
Exhibit 63: Allergan Plc - Segment focus
Exhibit 64: Allergan Plc - Key offerings
Exhibit 65: Allergan Plc - Key customers
Exhibit 66: Alnylam Pharmaceuticals Inc. - Vendor overview
Exhibit 67: Alnylam Pharmaceuticals Inc. - Business segments
Exhibit 68: Alnylam Pharmaceuticals Inc. - Organizational developments
Exhibit 69: Alnylam Pharmaceuticals Inc. - Key offerings
Exhibit 70: Alnylam Pharmaceuticals Inc. - Key customers
Exhibit 71: Amgen Inc. - Vendor overview
Exhibit 72: Amgen Inc. - Business segments
Exhibit 73: Amgen Inc. - Organizational developments
Exhibit 74: Amgen Inc. - Geographic focus
Exhibit 75: Amgen Inc. - Key offerings
Exhibit 76: Amgen Inc. - Key customers
Exhibit 77: Celgene Corp. - Vendor overview
Exhibit 78: Celgene Corp. - Business segments
Exhibit 79: Celgene Corp. - Organizational developments
Exhibit 80: Celgene Corp. - Geographic focus
Exhibit 81: Celgene Corp. - Key offerings
Exhibit 82: Celgene Corp. - Key customers
Exhibit 83: GlaxoSmithKline Plc - Vendor overview
Exhibit 84: GlaxoSmithKline Plc - Business segments
Exhibit 85: GlaxoSmithKline Plc - Organizational developments
Exhibit 86: GlaxoSmithKline Plc - Geographic focus
Exhibit 87: GlaxoSmithKline Plc - Segment focus
Exhibit 88: GlaxoSmithKline Plc - Key offerings
Exhibit 89: GlaxoSmithKline Plc - Key customers
Exhibit 90: Ionis Pharmaceuticals Inc. - Vendor overview
Exhibit 91: Ionis Pharmaceuticals Inc. - Business segments
Exhibit 92: Ionis Pharmaceuticals Inc. - Organizational developments
Exhibit 93: Ionis Pharmaceuticals Inc. - Key offerings
Exhibit 94: Ionis Pharmaceuticals Inc. - Key customers
Exhibit 95: Johnson & Johnson Services Inc. - Vendor overview
Exhibit 96: Johnson & Johnson Services Inc. - Business segments
Exhibit 97: Johnson & Johnson Services Inc. - Organizational developments
Exhibit 98: Johnson & Johnson Services Inc. - Geographic focus
Exhibit 99: Johnson & Johnson Services Inc. - Segment focus
Exhibit 100: Johnson & Johnson Services Inc. - Key offerings
Exhibit 101: Johnson & Johnson Services Inc. - Key customers
Exhibit 102: Pfizer Inc. - Vendor overview
Exhibit 103: Pfizer Inc. - Business segments
Exhibit 104: Pfizer Inc. - Organizational developments
Exhibit 105: Pfizer Inc. - Geographic focus
Exhibit 106: Pfizer Inc. - Segment focus
Exhibit 107: Pfizer Inc. - Key offerings
Exhibit 108: Pfizer Inc. - Key customers
Exhibit 109: Takeda Pharmaceutical Co. Ltd. - Vendor overview
Exhibit 110: Takeda Pharmaceutical Co. Ltd. - Business segments
Exhibit 111: Takeda Pharmaceutical Co. Ltd. - Organizational developments
Exhibit 112: Takeda Pharmaceutical Co. Ltd. - Geographic focus
Exhibit 113: Takeda Pharmaceutical Co. Ltd. - Key offerings
Exhibit 114: Takeda Pharmaceutical Co. Ltd. - Key customers
Exhibit 115: Validation techniques employed for market sizing
Exhibit 116: Definition of market positioning of vendors
Note: Product cover images may vary from those shown
3 of 3
LOADING...
4 of 3
- AbbVie Inc.
- Allergan Plc
- Alnylam Pharmaceuticals Inc.
- Amgen Inc.
- Celgene Corp.
- GlaxoSmithKline Plc
- Ionis Pharmaceuticals Inc.
- Johnson & Johnson Services Inc.
- Pfizer Inc.
- Takeda Pharmaceutical Co. Ltd.
Note: Product cover images may vary from those shown
